Mobile Site ›

Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation

An Update



Subscribe

Receive notification when new Hot Topics are published:

Clinical Utility of AGID Evaluation

Slide 17

April 2012

This then can help distinguish autoimmune gastrointestinal dysmotility from chemotherapy side effects. Finally, a rising antibody titer in a previously seropositive patient can suggest cancer recurrence.

Clinical Utility of AGID Evaluation

 


Jump to section:


Key